Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Int. braz. j. urol ; 46(2): 185-193, Mar.-Apr. 2020. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1090573

RESUMEN

ABSTRACT Objective To evaluate the effects of solifenacin, darifenacin, and propiverine on nasal-, subfoveal-, temporal choroidal thicknesses (NCT, SFCT, TCT), intraocular pressure (IOP) and pupil diameter (PD). Materials and Methods Patients with overactive bladder (OAB) diagnosed according to The International Continence Society were administered with solifenacin, darifenacin or propiverine on a daily basis between November 2017 and May 2018. NCT, SFCT, TCT, IOP, and PD of these patients were measured and compared as initial, fourth and twelfth weeks. Results A total of 165 patients (330 eyes) with OAB were evaluated. Solifenacin (n=140) significantly reduced IOP from 17.30±2.72 mmHg to 16.67±2.56 mmHg (p=0.006) and 16.57±2.41 mmHg (p=0.002), at the fourth and twelfth weeks, respectively. Darifenacin (n=110) significantly reduced NCT from 258.70±23.96 μm to 257.51±22.66 μm (p=0.002) and 255.36±19.69 μm (p=0.038), at the fourth and twelfth weeks, respectively. Propiverine (n=80) significantly increased PD from 4.04±0.48 mm to 4.08±0.44 mm (p=0.009) and 4.09±0.45 mm (p=0.001), at the fourth and twelfth weeks, respectively. Conclusion These findings can help to decide appropriate anticholinergic drug choice in OAB patients. We finally suggest further well-designed randomized prospective studies with a larger population to evaluate the anticholinergic-related complications in eyes.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Anciano , Anciano de 80 o más Años , Adulto Joven , Pirrolidinas/efectos adversos , Bencilatos/efectos adversos , Benzofuranos/efectos adversos , Pupila/efectos de los fármacos , Coroides/efectos de los fármacos , Antagonistas Muscarínicos/efectos adversos , Succinato de Solifenacina/efectos adversos , Presión Intraocular/efectos de los fármacos , Pirrolidinas/administración & dosificación , Bencilatos/administración & dosificación , Benzofuranos/administración & dosificación , Estudios Prospectivos , Estudios de Seguimiento , Antagonistas Muscarínicos/administración & dosificación , Vejiga Urinaria Hiperactiva/tratamiento farmacológico , Succinato de Solifenacina/administración & dosificación , Persona de Mediana Edad
3.
Braz. j. med. biol. res ; 46(8): 643-649, ago. 2013. graf
Artículo en Inglés | LILACS | ID: lil-684525

RESUMEN

MP [4-(3′,3′-dimethylallyloxy)-5-methyl-6-methoxyphthalide] was obtained from liquid culture of Pestalotiopsis photiniae isolated from the Chinese Podocarpaceae plant Podocarpus macrophyllus. MP significantly inhibited the proliferation of HeLa tumor cell lines. After treatment with MP, characteristic apoptotic features such as DNA fragmentation and chromatin condensation were observed in DAPI-stained HeLa cells. Flow cytometry showed that MP induced G1 cell cycle arrest and apoptosis in a dose-dependent manner. Western blotting and real-time reverse transcription-polymerase chain reaction were used to investigate protein and mRNA expression. MP caused significant cell cycle arrest by upregulating the cyclin-dependent kinase inhibitor p27KIP1 protein and p21CIP1 mRNA levels in HeLa cells. The expression of p73 protein was increased after treatment with various MP concentrations. mRNA expression of the cell cycle-related genes, p21CIP1 , p16INK4a and Gadd45α, was significantly upregulated and mRNA levels demonstrated significantly increased translation of p73, JunB, FKHR, and Bim. The results indicate that MP may be a potential treatment for cervical cancer.


Asunto(s)
Humanos , Apoptosis/efectos de los fármacos , Benzofuranos/administración & dosificación , Endófitos/química , Puntos de Control de la Fase G1 del Ciclo Celular/efectos de los fármacos , Xylariales/química , Proteínas Reguladoras de la Apoptosis/genética , Benzofuranos/aislamiento & purificación , Proteínas de Ciclo Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , /efectos de los fármacos , /efectos de los fármacos , Proteínas de Unión al ADN/efectos de los fármacos , Citometría de Flujo , Factores de Transcripción Forkhead/efectos de los fármacos , Cycadopsida , /efectos de los fármacos , Células HeLa , Proteínas Nucleares/efectos de los fármacos , Reacción en Cadena en Tiempo Real de la Polimerasa , Transcripción Genética , Factores de Transcripción/efectos de los fármacos , Proteínas Supresoras de Tumor/efectos de los fármacos
4.
Yonsei Medical Journal ; : 845-853, 2013.
Artículo en Inglés | WPRIM | ID: wpr-99054

RESUMEN

PURPOSE: Postoperative ileus (POI) is an impairment of coordinated gastrointestinal (GI) motility that develops as a consequence of abdominal surgery and is a major factor contributing to patient morbidity and prolonged hospitalization. The aim of this study was to investigate the effects of different 5-hydroxytryptamine 4 (5-HT4) receptor agonists, which stimulate excitatory pathways, on a POI model. MATERIALS AND METHODS: The experimental model of POI in guinea pigs was created by laparotomy, gentle manipulation of the cecum for 60 seconds, and closure by suture, all under anesthesia. Different degrees of restoration of GI transit were measured by the migration of charcoal. Colonic transit was indirectly assessed via measurement of fecal pellet output every hour for 5 hours after administration of various doses of mosapride, tegaserod, prucalopride, and 5-HT. RESULTS: Charcoal transit assay showed that various 5-HT4 receptor agonists can accelerate delayed upper GI transit in a dose-dependent manner. However, fecal pellet output assay suggested that only prucalopride had a significant effect in accelerating colonic motility in POI. CONCLUSION: Although mosapride, tegaserod, and prucalopride produce beneficial effects to hasten upper GI transit in the POI model, prucalopride administered orally restores lower GI transit as well as upper GI transit after operation in a conscious guinea pig. This drug may serve as a useful candidate for examination in a clinical trial for POI.


Asunto(s)
Animales , Masculino , Administración Oral , Benzamidas/farmacología , Benzofuranos/administración & dosificación , Carbón Orgánico/farmacocinética , Colon/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Motilidad Gastrointestinal/efectos de los fármacos , Cobayas , Ileus/cirugía , Indoles/farmacología , Laparotomía , Morfolinas/farmacología , Complicaciones Posoperatorias/tratamiento farmacológico , Serotonina/farmacología , Agonistas del Receptor de Serotonina 5-HT4/farmacología
5.
Rev. cuba. med ; 24(11): 1199-208, nov. 1985. ilus, tab
Artículo en Español | LILACS | ID: lil-40085

RESUMEN

Se indican los aspectos farmacoclínicos de la amiodarona y se revisan algunos aspectos que tienen vigencia en la práctica clínica diaria. Se informa el uso de la amiodarona como uno de los fármacos antiarrítmicos más importantes de la última década y los beneficios e inconvenientes que puede obtener un paciente con su uso


Asunto(s)
Humanos , Arritmias Cardíacas/tratamiento farmacológico , Benzofuranos , Benzofuranos/administración & dosificación , Benzofuranos/farmacología , Benzofuranos/toxicidad , Química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA